☆ 4.6 Letter

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderateto-severe psoriasis through 2 years of treatment: Results from the CLEAR study

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Volume 81, Issue 6, Pages 1405-1409

Publisher

MOSBY-ELSEVIER

DOI: 10.1016/j.jaad.2019.04.045

Keywords

Funding

Novartis Pharma AG, Basel, Switzerland

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderateto-severe psoriasis through 2 years of treatment: Results from the CLEAR study

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Publisher

MOSBY-ELSEVIER

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderateto-severe psoriasis through 2 years of treatment: Results from the CLEAR study

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Publisher

MOSBY-ELSEVIER

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper